Skip to main content

FDA Seeks Public Input on Patient-Focused Drug Development for Stimulant Use Disorder

September 24, 2020

The U.S. Food & Drug Administration announced that it will conduct a virtual public meeting on patient-focused drug development (PFDD) for stimulant use disorder, and the administration is seeking input from individuals and family members impacted by cocaine, methamphetamine, crystal meth and prescription stimulant misuse.

Specifically, FDA seeks public input on:

  • Health effects and daily impacts on users’ condition
  • Impacts of opioid and polysubstance use, if applicable
  • Treatment goals
  • Factors considered when seeking treatment
  • Impact of COVID-19

The meeting, which is free to attend, is scheduled to take place from 12:30 p.m. to 5 p.m. ET on Oct. 6. To register in advance, visit the FDA website.

Back to Top